Investigation and pending multiple lawsuits against Organon in connection with its manufature of NuvaRing, which is a vaginal contraceptive ring.
NuvaRing contains estrogen and progestin hormones. However, the type of progestin used in the NuvaRing (etonogestrel), is considered a third-generation progestin and is associated with a greater risk for developing blood clots than the type of progestin that is used in most birth control pills. Since the NuvaRing became available in 2002, the U.S. Food and Drug Administration (FDA) has received many reports of adverse events associated with the use of the NuvaRing. The most dangerous side effect is blood clotting, which can lead to a heart attack, stroke, or even death. In 2005, the FDA required Organon to change the NuvaRing label to more accurately reflect the risks associated with it.
Do not change medications without first consulting your doctor.
Name (Stock Symbol)
Organon BioSciences merged with Schering-Plough Corporation d is now part of that pharmaceutical company.
The information provided on ClassAdvocate.com is general in nature,
does not apply to any particular factual situation, and is not and
should not be taken as legal or other professional advice. We make no
commitment or warranty that the factual, legal or any other information
on ClassAdvocate.com, or on any linked website, is accurate, complete,
error-free, or current. As such, you should not rely on such information,
and should seek professional advice if and as you determine appropriate.
ClassAdvocate.com is not a lawyer referral service, and no attorney-client
or confidential relationship is or should be formed by use of the site.
The investigations listed on ClassAdvocate.com are attorney advertisements
and do not in any way constitute a referral or endorsement by ClassAdvocate.com
or any approved or authorized lawyer referral service.